Taiko Pharmaceutical Co.,Ltd.
4574.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.91B
Close$
Share Statistics
| Market cap | $12.91 Billion |
|---|---|
| Enterprise Value | $10.42 Billion |
| Dividend Yield | $3.30 (1.28%) |
| Earnings per Share | $18.37 |
| Beta | 0.05 |
| Outstanding Shares | 50,259,987 |
Return
| Return on Equity | 8.17% |
|---|---|
| Return on Assets | 6.20% |
| Return on Invested Capital | 6.13% |
Valuation & Multiples
| P/E Ratio | 18.77 |
|---|---|
| PEG | -1.61 |
| Price to Sales | 1.96 |
| Price to Book Ratio | 1.54 |
| Enterprise Value to Revenue | 1.57 |
| Enterprise Value to EBIT | 17.54 |
| Enterprise Value to Net Income | 15 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.29 B
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$2.28 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Taiko Pharmaceutical Co.,Ltd.
220 employees
CEO: Takashi Shibata Taiko Pharmaceutical Co.,Ltd. operates primarily in the pharmaceutical sector and the field of infection prevention. The company manufactures and distributes various over-the-counter medications, including its well-known Seirogan and Sei...